Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: MNPR
TL;DR
Monopar Therapeutics filed an 8-K today, likely containing important updates for investors.
AI Summary
On October 15, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Monopar Therapeutics is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational details that would indicate a high risk.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- October 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Monopar Therapeutics?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported was on October 15, 2024.
In which state is Monopar Therapeutics incorporated?
Monopar Therapeutics Inc. is incorporated in Delaware.
What is the principal executive office address for Monopar Therapeutics?
The principal executive office is located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
Does the filing excerpt mention any specific financial results or material events?
No, the provided excerpt does not detail specific financial figures or material events.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-10-15 08:00:09
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20241014_8k.htm (8-K) — 25KB
- ex_732220.htm (EX-99.1) — 12KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-031184.txt ( ) — 181KB
- mnpr-20241015.xsd (EX-101.SCH) — 3KB
- mnpr-20241015_def.xml (EX-101.DEF) — 12KB
- mnpr-20241015_lab.xml (EX-101.LAB) — 16KB
- mnpr-20241015_pre.xml (EX-101.PRE) — 12KB
- mnpr20241014_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 15, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing it has filed a provisional patent application pertaining to therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotpes with targeting agents. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated October 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: October 15, 2024 By: /s/ Karthik Radhakrishnan Name: Karthik Radhakrishnan Title: Chief Financial Officer